Peptinov

Peptinov is a clinical-stage biotech focused on discovering and developing novel peptide drugs for chronic inflammatory diseases. The company's lead candidate, P1, is in Phase 1/2 development for systemic sclerosis, targeting a novel mechanism to address fibrosis. Peptinov's technology platform enables the rational design of peptides with enhanced stability and specificity, aiming to overcome limitations of traditional biologics and small molecules in inflammatory disorders.

Proprietary peptide design and optimization platform for developing therapeutic peptides with enhanced stability, specificity, and pharmacokinetic properties targeting inflammatory pathways.

Faces competition from large pharma with approved therapies for systemic sclerosis and numerous biotechs developing novel approaches. Differentiation through proprietary peptide platform and focus on novel targets within inflammatory pathways.